Huntingdon Life Sciences Acquires Harlan Laboratories

Huntingdon Life Sciences(HLS) recently announced that it has acquired Harlan Laboratories. The new company will have two operating divisions: Research Models and Services and Contract Research Services.

This acquisition creates a leading global organization offering full service, non-clinical, contract research and research models and services.  The increased scale of the combined venture, approaching half a billion dollars in annual revenue, provides a strong platform for future growth and investment.

Brian Cass, CEO of Huntingdon Life Sciences, commented, "We are excited by the acquisition of Harlan, a highly respected leader in their market sectors. This acquisition is precisely in line with our strategy to broaden our support for the pharmaceutical, crop protection and chemical industries, as well as universities, government, and other research organizations. Our two companies have a long heritage and together we will maintain and build on our reputation for high quality science and innovation."

Harlan CEO Hans Thunem said, "Merging these two leading companies, with their complementary product and service offerings, positions the combined organization as a global leader in supporting the growing market for outsourced research and development. Brian and his newly expanded team bring enormous depth and experience to the increasingly complex challenges facing non-clinical and pre-clinical researchers."